SeaSpine Investor Update

1+1 $234-236M FY 2022 Revenue (22-23% Growth) 11-12% R&D Expense as % of Total Revenue 150-200BPS Adj. GM % Expansion (65.2-65.7%) oin $3.5-4.5M Adj. EBITDA Loss Reduction (15-20%) Ⓒ2022 SeaSpine Orthopedics Corporation. All rights reserved | 20 Guidance 2022 Financial guidance information is as of August 2, 2022, based on guidance provided by SeaSpine leadership on that date. Inclusion of this information in this presentation is not a confirmation or an update of, and should not be construed or otherwise assumed to reflect any confirmation or update of, that guidance by SeaSpine leadership as of any date other than August 2, 2022. Adjusted Gross Margin and Adjusted EBITDA Loss are non-GAAP financial measures that are not calculated in accordance with generally accepted accounting principles, or GAAP. These non-GAAP financial measures should not be considered a replacement for, and should be read together with, the most directly comparable GAAP financial measures. Reconciliations to the most directly comparable GAAP measures are provided in Appendix A to this presentation. SeaSpine

View entire presentation